Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial

MLA

Mohammadreza Moslemi, et al. “Evaluating the Effect of Edaravone on Clinical Outcome of Patients with Severe COVID-19 Admitted to ICU: A Randomized Clinical Trial.” Inflammopharmacology, vol. 30, June 2022, pp. 1277–82. EBSCOhost, https://doi.org/10.1007/s10787-022-01001-2.

APA

Mohammadreza Moslemi, Seyyedeh Mina Hejazian, Molod Shaddelan, Fatemeh Javanali, Alireza Mirghaffari, Armin Sadeghi, Hamed Valizadeh, Akbar Sharifi, Morteza Haramshahi, Mohammadreza Ardalan, & Sepideh Zununi Vahed. (2022). Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial. Inflammopharmacology, 30, 1277–1282. https://doi.org/10.1007/s10787-022-01001-2

Chicago

Mohammadreza Moslemi, Seyyedeh Mina Hejazian, Molod Shaddelan, Fatemeh Javanali, Alireza Mirghaffari, Armin Sadeghi, Hamed Valizadeh, et al. 2022. “Evaluating the Effect of Edaravone on Clinical Outcome of Patients with Severe COVID-19 Admitted to ICU: A Randomized Clinical Trial.” Inflammopharmacology 30 (June): 1277–82. doi:10.1007/s10787-022-01001-2.